FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* AMELIO GILBERT F							2. Issuer Name and Ticker or Trading Symbol GALECTIN THERAPEUTICS INC										tionship o all applic Directo	able)	g Pers	son(s) to Iss 10% Ov	
(Last) (First) (Middle) C/O GALECTIN THERAPEUTICS, INC. 4960 PEACHTREE INDUSTRIAL BLVD., ST				ΓE 240	01/	3. Date of Earliest Transaction (Month/Day/Year) 01/21/2019											below)	(give title		Other (s below)	
(Street) NORCROSS GA 30071 (City) (State) (Zip)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
Date					te			2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)					4 and Securitie Benefici Owned F		s ally ollowing	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership
										Code	v	Amount		(A) or (D)	Price		Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)
Common Stock 01/21					/2019	2019				M		41,50		A	\$0.8	\$0.89		1,461		D	
Common Stock 01/21					/2019	9				F		7,776	5	D	\$4.75		153,685			D	
Common Stock 01/21					/2019	9				M		62,25	0	A	\$2.39		215,935			D	
Common Stock 01/21					/2019	9				F		31,32	2	D	\$4.75		184,614			D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	d 4. Date, Ti	ransaction ode (Instr.		5. Number of		6. Ex		ercisa Date	able and	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Amount s security	De Se	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct (or Indir (I) (Inst	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				С	ode	v	(A)	(D)	Da Ex	ate cercisab		xpiration ate	Title		Amount or Number of Shares						
Stock option	80 A9	01/21/2019			м			<i>4</i> 1 500		(1)		2/15/2026	Cor	nmon	11 500		næ	0		D	

(1)

(2)

41,500

62,250

Explanation of Responses:

\$0.89

\$2,39

- 1. The options vested 100% on December 14, 2017.
- 2. The options vested 100% on December 14, 2018.

Remarks:

(right to

buy) Stock option (right to

buy)

/s/ Jack Callicutt, by power of

41,500

62,250

\$0

\$0

01/23/2019

0

0

D

D

<u>attorney</u>

Stock

Common

Stock

12/15/2026

12/14/2027

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

01/21/2019

01/21/2019

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

M

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.